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Trachoma is caused by Chlamydia trachomatis and is the leading
infectious cause of preventable blindness globally. For trachoma
control, the World Health Organization (WHO) promotes the
SAFE strategy, an integrated program of 1) eyelid Surgery to
correct the in-turned eyelashes associated with severe trachoma
and stops pain and minimizes risk of corneal damage; 2) Antibiotic
treatment for active trachoma using single-dose oral azithromycin
or tetracycline eye ointment; 3) Facial cleanliness through
sustained behavior change to reduce transmission; and 4)
Environmental improvement, to increase access to water and
sanitation [1,2]. The A, F, and E components of SAFE have been
designed to treat ocular Chlamydia infection and reduce the risk of
trachoma transmission, such that blinding trachoma is eliminated.
There has been considerable debate as to whether mass
treatment with antibiotics alone can eliminate trachoma. In
Tanzania, a study by Solomon et al., conducted in a single isolated
village, showed that one mass treatment with azithromycin and
periodic tetracycline eye ointment had reduced ocular infection
with C. trachomatis from 9.5% to 0.1% 24 months post-treatment
[3]. Following a second round of mass azithromycin treatment at
24 months, no C. trachomatis DNA was detected on ocular swabs
from the entire community at 60 months after baseline [4]. In The
Gambia, a study of 12 villages reported that a single mass
treatment with azithromycin was probably sufficient for long-
lasting control of C. trachomatis; however, re-infection occurred
through contact with untreated communities [5]. In contrast, a
second single village study from Tanzania showed that after two
rounds of mass treatment with azithromycin, ocular infection with
C. trachomatis was still present, and neither clinical trachoma nor
infection had been eliminated [6,7].
The paper by Lakew et al. provides the best data yet
contributing to the elimination debate [8]. It is an excellent 42-
month longitudinal assessment of ocular Chlamydia infection
following four biannual mass treatments, at months 0–18 in 16
communities in Gurage zone of Southern Nations Nationalities
and Peoples Region, a trachoma hyper-endemic area of Ethiopia.
The authors have previously reported findings from studies
conducted in the same study area: four concluded that local
elimination of ocular Chlamydia infection in hyper-endemic areas
was feasible with biannual mass treatment with azithromycin [9–
12]; one found that infection was not eliminated after a single dose
of mass azithromycin [13]; and two indicated that mass treatment
with azithromycin provided protection for both treated and
untreated individuals [14,15].
Unlikeprevious studies in Tanzania and The Gambia, the Lakew
et al. [8] study includes more villages (16), conducted biannual mass
treatment with azithromycin, and provided a follow-up of 42
months. There was considerable variation between the villages and
none of them performed exactly as the mean of the 16. In other
words, there was no ‘‘average’’ or ‘‘typical’’ village. This argues
stronglythat findingsfrom the single villagestudies[4,6,7]shouldbe
interpreted with caution, or even considered as anecdotal.
The field teams did an excellent job in achieving and
documenting high coverage with antibiotics, and attained
impressive results. The mean study coverage was over 90% with
100% of the eligible population reported for several villages.
Although the current WHO guidelines suggest aiming for ‘‘a
minimum’’ of 80% coverage, programs should not consider this as
the goal, but aim for 100% and document the true coverage. It
may be possible for programs to routinely achieve above 85%
coverage—the Lakew et al. study suggests that this would greatly
improve impact.
This study used four rounds of antibiotic distributed 6 months
apart. Decline in infection was rapid and deep (from an average
of 63.5% to 2.6%). Yet, the rebound was also steep, roughly
doubling at each successive 6-month period after treatment
stopped to 25.2% after 24 months. During the course of the study
nine of 16 villages achieved local elimination of ocular Chlamydia
in children (i.e., a prevalence of infection of 0%). Importantly,
none of these villages maintained a 0% prevalence through to the
42-month follow-up, demonstrating that local elimination is not
the same as sustainable control as previously suggested [9–12].
Re-infection took place from somewhere, and once it did,
transmission was rapid, as the behaviors and environmental
conditions that favored trachoma had not been altered. The
message for trachoma programs is very clear: however much we may be
tempted to, if we base trachoma control in hyper-endemic areas solely on
antibiotic distribution, success is not likely.
Operational decisions by national trachoma control programs
are made on the basis of clinical signs of trachoma and not nucleic
acid amplification tests (NAATs). The merits of NAATs compared
to clinical signs remains a controversial issue. A recent review by
Wright and Taylor critically explored the discrepancies that exist
between the clinical signs and NAATs and attributes this largely to
the kinetics of the disease [16]. Although laboratory tests have a
role in complementing clinical signs in monitoring antibiotic
treatment, they have limitations because of their exorbitant costs
and impracticality under field conditions. Yet, all national
trachoma control programs have access to clinical signs that
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none routinely uses NAATs. Lakew et al. provided prevalence of
clinical signs for the baseline survey, but not for the follow-up
surveys. Inclusion of both trachomatous inflammation-follicular
(TF) and trachomatous inflammation-intense (TI) as separate
indicators for the follow-up results may have helped elucidate our
understanding of the disparity between these signs and positivity
by NAAT. Additionally, it would have been interesting to see the
effect of the multiple treatments on the clinical signs, and on TI in
particular since it appears most susceptible to intervention [17,18];
is associated with higher infection rates [19] and a greater load of
C. trachomatis DNA [20,21]; and is more closely linked to
progression to cicatricial trachoma [22].
There is an idea that three annual rounds of azithromycin will
result in elimination of ocular infection and districts can
‘‘graduate’’ from implementation programs. Forecasts for global
azithromycin demand are based on this assumption. These data
do not support that idea. Programs should not expect to graduate
districts after 3 years, but should reassess the trachoma prevalence
after at least 3 years and expect to continue implementation rather
than stop at the risk of losing the ground gained. The Pfizer
donation of azithromycin is greatly appreciated and has been
tremendously important in breathing life into trachoma control
programs. As the country programs expand to recruit more people
and aim for elimination of blinding trachoma, the global demand
for donated azithromycin is increasing. The 135 million doses
pledged in 2003 have been consumed, and there has been no clear
public declaration for a continued and expanded donation—
although the annual quantity of azithromycin generously provided
by Pfizer has continued to rise in 2009. Should the capacity of
programs to use azithromycin exceed the capacity of the donor to
produce it, there will be a need for decisions on the most rational
use of the resource to be made. Options for the most rational use
of azithromycin may include focusing on the most endemic
countries; restricting treatment to children (the reservoir of
infection); an attack phase of annual treatment for 3 years
followed by a maintenance phase of treatment once in every
2 years; or basing decisions to treat on TI rather than TF. The
data provided by Lakew et al. show that arbitrary graduation after
three annual treatments alone is not one of them.
There is little doubt that the mass distribution of azithromycin
for trachoma control is the most effective way of rapidly reducing
ocular infection with C. trachomatis, and that mass distribution will
probably have many population level collateral benefits beyond
trachoma control. However, unless accompanied by effective facial
cleanliness and environmental improvements, mass treatment
alone will not result in eliminating trachoma in the most affected
areas. The vast data provided by the team in Gurage zone are a
sobering indication that we cannot rely on drug distribution alone
to eliminate transmission of trachoma and that there remains an
urgent need for substantial investment in hygiene promotion,
water, and sanitation in addition to drug distribution to release the
world from the tragedy of blinding trachoma.
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